Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/12/2019
SIETES contiene 92850 citas

 
 
 1 a 20 de 39 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Fibromyomes utérins hémorragiques. Adapter le traitement à chaque femme. Prescrire 2014;34:115-22. [Ref.ID 97129]
2.Tiene citas relacionadas
Middleton LJ, Champaneria R, Daniels JP, Bhattacharya S, Cooper KG, Hilken NH, O'Donovan P, Gannon M, Gray R, Khan KS, on behalf of the International Heavy Menstrual Bleeding Individual Patient Data Meta-analysis Collaborative Group. Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patients. BMJ 2010;341:379. [Ref.ID 89184]
3.Tiene citas relacionadas
Clarke J. Treatment of heavy menstrual bleeding. BMJ 2010;341:353-4. [Ref.ID 89177]
4. Cita con resumen
Schnipper LE. Update in oncology. Ann Intern Med 2007;147:775-82. [Ref.ID 81819]
5.Tiene citas relacionadas
Altman D, Granath F, Cnattingius S, Falconer C. Hysterectomy and risk of stress-urinary-incontinence surgery: nationwide cohort study. Lancet 2007;370:1494-9. [Ref.ID 81373]
6.Tiene citas relacionadas
Magos A. Does hysterectomy cause urinary incontinence?. Lancet 2007;370:1462-3. [Ref.ID 81363]
7.Tiene citas relacionadas
Tulandi T. Treatment of uterine fibroids - is surgery obsolete?. N Engl J Med 2007;356:411-3. [Ref.ID 78948]
8. Cita con resumen
Chen WY, Manson JE, Hankinson SE, Rosner B, Holmes MD, Willett WC, Colditz GA. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027-32. [Ref.ID 76950]
9.Tiene citas relacionadas
Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658-67. [Ref.ID 76774]
10.Tiene citas relacionadas Cita con resumen
Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT, for the WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57. [Ref.ID 76773]
11. Cita con resumen
Cook G, Depares J, Singh M, McElduff P. Readmission after hysterectomy and prophylactic low molecular weight heparin: retrospective case-control study. BMJ 2006;332:819-20. [Ref.ID 76697]
12.
Brunner RL, Gass M, Aragaki A, Hays J, Granek I A, Woods N, Mason ES, Brzyski RG, Ockene J, Assaf AR, Lacroix A, Matthews K, Wallace R, for the Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy. Arch Intern Med 2005;165:1976-86. [Ref.ID 75061]
13.Tiene citas relacionadas
Edozien LC. Hysterectomy for benign conditions. BMJ 2005;330:1457-8. [Ref.ID 74193]
14. Cita con resumen
Moreira da Costa RJ, Krauss-Silva L. Systematic review and meta-analysis of antibiotic prophylaxis in abdominal hysterectomy. Cad Saude Publica 2004;20:175-89. [Ref.ID 73073]
15.Tiene citas relacionadas
Hurskainen R, Teperi J, Rissanen P, Aalto A-M, Greman S, Kivelä A, Kujansuu E, Vuorma S, Yliskoski M, Paavonen J. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia. Randomized trial 5-year follow-up. JAMA 2004;291:1456-63. [Ref.ID 69492]
16.Tiene citas relacionadas
Kuppermann M, Varner RE, Summitt RL, Learman LA, Ireland C, Vittinghoff E, Stewart AL, Lin F, Richter H E, Showstack J, Hulley SB, Washington AE, for the Ms Research Group. Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning. The medicine or surgery (Ms) randomized trial. JAMA 2004;291:1447-55. [Ref.ID 69491]
17.
18.Tiene citas relacionadas
Veronesi U, Maisonneuve P, Rotmensz N, Boyle P. Tamoxifen for breast cancer in hysterectomised women. Authors' reply. Lancet 2002;360:1785. [Ref.ID 64248]
19.Tiene citas relacionadas
Benson JR. Tamoxifen for breast cancer in hysterectomised women. Lancet 2002;360:1784-5. [Ref.ID 64247]
20.
Hurskainen R, Teperi J, Rissanen P, Aalto A-M, Kivelä A, Kujansuu E, Vuoma S, Yliskoski M, Paavonen J. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine sytem versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001;357:273-7. [Ref.ID 55011]
Seleccionar todas
 
 1 a 20 de 39 siguiente >>